Physician profile

John A Charles

Family Medicine · Syracuse, NY

NPI 1962489716

$998.44

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $118.99 2019-2020
Eisai INC. $95.72 2019-2020
Merck Sharp & Dohme LLC $85.72 2019-2020
Novo Nordisk INC $82.34 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $63.53 2019-2020
Glaxosmithkline, LLC. $60.72 2019-2020
Bausch Health US, LLC $58.70 2019-2020
Lilly USA, LLC $55.13 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $45.70 2019-2020
Sanofi-Aventis U.S. LLC $44.43 2019
Allergan, INC. $42.38 2019-2020
Astrazeneca Pharmaceuticals LP $36.98 2019-2020
Arbor Pharmaceuticals, INC. $34.42 2019
Amarin Pharma, INC. $31.05 2019
Abbott Laboratories $23.95 2019
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Teva Pharmaceuticals USA, INC. $22.59 2020
Kowa Pharmaceuticals America, INC. $18.94 2019
Abbvie INC. $18.41 2019
Amgen INC. $17.69 2019
Janssen Pharmaceuticals, INC $15.66 2019
Ibsa Pharma INC. $13.81 2020
Endo Pharmaceuticals INC. $11.58 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John A Charles

$998.44

in general payments reported 2019-2025

Years
2019-2020
Top company
Pfizer INC.

https://glasscript.com/doctor/224645/john-a-charles

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.